maccura(SZ:300463) Sou Hu Cai Jing·2025-05-22 10:05Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Maike Biological, within the medical device industry [1][2] - As of May 22, the company's stock closed at 11.7 yuan, down 1.68%, with a rolling PE ratio of 236.17 times and a total market capitalization of 7.166 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Maike Biological at the 118th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported an operating revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year [2] - The company's sales gross margin stands at 56.76% [2] - The company specializes in the research, production, sales, and related services of in vitro diagnostic products, with a wide range of testing reagents for various medical conditions [1]